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Background: We have recently described changes present in nigrostriatal termi­
nals after intraperitoneal administration of MG­132 and changes that occur in 
the walls of the rat lateral ventricle after intraventricular administration of 
MG­132, lactacystin and epoxomicin — different classes of proteasome inhibitors. 
Substances that inhibit ubiquitin­proteasome system (UPS) activity, are intensively 
studied due to their potential role as novel therapeutic strategies in the treatment 
of cancer and ischaemia­reperfusion injury in the brain. The aim of this study is to 
determine the influence of intraventricular administration of MG-132, lactacystin 
and epoxomicin on the level in the rat striatum synapsin I — one of the most 
prominent neuron-specific phosphoproteins in the brain. 
Materials and methods and Results: Two weeks after administration of studied 
proteasome inhibitors, substantial reduction (up to 80%) of synapsin I was ob­
served in the rat striatum. Because neurons, and especially dopaminergic ones, 
are sensitive to the depletion of proteasome function, we assume that observed 
synapsin I decrease may reflect changes in population of striatal neurons and/or 
nigrostriatal terminals. 
Conclusions: Understanding of cellular mechanisms standing behind our findings 
needs further studies, and could provide valuable contribution to the discussion 
on the mechanisms linking UPS inhibition and survival of neurons. (Folia Morphol 
2015; 74, 4: 428–433)
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INTRODUCTION
Constant acquirement of new knowledge and 
information, and the development of new laboratory 
techniques and new diagnostic laboratory methods 
allow scientists to see well established analytical tools 
from a different perspective, and in many cases those 
tools can be used for a new purpose. Neuronal nucle-
ar antigen (NeuN) antibody recognises a neuron-spe-
cific nuclear protein in vertebrates, and is commonly 
used as a reliable marker to detect most postmitotic 
neuronal cell types in neuroscience, developmental 
biology, and stem cell research fields as well as diag-
nostic histopathology [13]. However, NeuN antibody 
has been introduced in early 90’s [18], its protein 
target, the Fox-3 gene product, was recognised about 
15 years later [13]. The scientific group which reve-
aled this, also pointed that a protein cross-reactive 
with anti-NeuN antibodies, present in immunoblots 
as 65–75 kDa bands, is the synaptic vesicle protein, 
synapsin I. Further experiments on protein samples 
from synapsin II and synapsin III knockout mice and 
from compound knockout animals for synapsin I 
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and II, and I, II and III supported the conclusion that 
the 65–75 kDa NeuN-cross-reactive bands are strictly 
dependent on the presence of synapsin I [16]. 
Synapsin I, one of the most prominent phospho-
proteins in the brain, is the best characterised member 
of the synapsins family. In mammals, the synapsins 
consist of more than ten isoforms of neuron-specific 
phosphoproteins, which are encoded by three genes 
— designated synapsins I, II and III — and are thought 
to be involved in the regulation of neurotransmitter 
release. The synapsins, associated with the cytoplasmic 
surface of synaptic vesicles, are responsible for regula-
tion of neurotransmitter release in presynaptic termi-
nals of mature synapses and accelerate development 
of the nervous system [8]. It has been also proposed 
that, the synapsins may play a role in the formation and 
maintenance of synapses (synapsin I and II), synaptic 
vesicle fusion (synapsin I, II, and III) and its protein 
stabilisation (synapsin I and II), neurite elongation (sy-
napsin I, II, and III) and neurogenesis (synapsin III) [24]. 
Lately, it has been postulated that synapsin cellular tur-
nover is regulated by the ubiquitin-proteasome system 
(UPS) [6, 14], the main system responsible for protein 
degradation in eukaryotic cells, which has currently 
become attractive research topic due to its involvement 
in neurodegenerative pathogenesis during aging, the 
inflammatory response, and the dynamics of tumour 
development [22, 26].
We have recently described changes present in 
nigrostriatal terminals after intraperitoneal admini-
stration of MG-132 [28] and changes that occur in the 
walls of the rat lateral ventricle after intraventricular 
administration of MG-132, lactacystin and epoxomi-
cin [27] — different classes of proteasome inhibitors. 
Substances that inhibit UPS activity are intensively 
studied due to their potential role as novel therapeutic 
strategies in the treatment of cancer and ischaemia-
-reperfusion injury in the brain [12]. The aim of this 
study is to determine the influence of intraventricular 
administration of selected covalent proteasome inhi-
bitors — MG-132 (an example of peptide aldehydes), 
lactacystin (an example of b-lactones and derivatives) 
and epoxomicin (an example of epoxyketones) on 
level of synapsin I protein in the rat striatum.
MATERIALS AND METHODS
Animals
Twenty adult (postnatal day 90) male Wistar rats 
(initial weight between 230 and 270 g) were used in 
this study. All rats were bred until they reached the 
appropriate age in the Tri-City Academic Laboratory 
Animal Centre — Research and Services Centre. All 
of the animals were bred behind a sanitary-hygienic 
barrier, which is supported by HEPA filters. The rats 
were kept in air-conditioned spaces under a constant 
temperature (22 ± 2°C) and humidity (55 ± 10%), 
with a defined lighting regimen (lights on from 
7:00 a.m. to 7:00 p.m.). All rats were housed socially 
in polysulphone cages (size T. IV) with an area of 1875 
cm2 and a height of 195 mm (3–4 animals per cage) 
strewn with powderless sawdust from deciduous 
trees. The rats were fed a standard food mixture for 
rodents, which is manufactured by SSNIFF (Spezial-
diäten GmbH, Germany). Both food and water were 
autoclaved before being served to the animals and 
water was available ad libitum. All of the rats were 
supplied to the Department Animal Centre 2 weeks 
before our experiments began and were housed in 
similar conditions. In this study, the rats’ care and 
treatment was performed in strict accordance with 
the recommendations given in the “Guide for the care 
and use of laboratory animals” of the Polish National 
Committee on the Ethics of Animal Experiments. 
The experimental procedures were reviewed and ap-
proved by the 3rd Local Committee on the Ethics of 
Animal Experiments in Gdansk (Local Committee of 
the Medical University of Gdansk — Permit Number: 
08-2007). All efforts were made to reduce the number 
of animals and to minimise their suffering.
Proteasome inhibitor administration
The animals were randomly divided into four 
groups. All rats were anesthetised with an intrape-
ritoneal administration of fentanyl (1 mg/kg) and 
dehydrobenzperidol (0.2 mg/kg). The animals were 
fixed in a stereotaxic frame (Trend Wells, USA) under 
sterile conditions, and after an incision in the skin, 
a small craniectomy was made above the selected 
cortical area. The cerebral cortex was exposed after 
an incision of the dura mater. A glass micropipette 
coated with silicone gel was inserted through the 
cerebral cortex into the right lateral ventricle, based 
on the stereotaxic coordinates from the bregma point: 
0.6 mm posteriorly, 1.5 mm laterally, and 3.8 mm 
ventrally [19]. Pressure injections were made using 
a 5 µL Hamilton syringe at a rate of 0.8 µL/min. The 
first group, which is referred to as the controls (n = 5) 
in the subsequent text, consisted of animals that re-
ceived a 4 µL injection of 100% dimethyl sulphoxide 
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(DMSO; Sigma-Aldrich, St Louis, MO). The second 
group is referred to as MG-132 (n = 5), the third 
group as lactacystin (n = 5) and the fourth group 
as epoxomicin (n = 5) consisted of animals that re-
ceived injections of 32 µg MG-132 (Boston Biochem 
Inc.; cat # I-130.5, lot # 3570428), 20 µg lactacystin 
(Boston Biochem Inc.; cat # I-115) or 4 µg epoxomi-
cin (Boston Biochem Inc.; cat # I-110), respectively; 
all proteasome inhibitors were dissolved in 4 µL of 
DMSO. The doses administered to the animals were 
based on those previously reported in the literature 
[9, 25]. After each injection, the micropipette was 
held in place for at least 5 min to prevent leakage of 
the administered substance and then gently retracted, 
and the wound was surgically closed. The experimental 
endpoints have been set at 2 weeks after the surgery. 
Tissue collection and preparation for Western blot
Two weeks after intraventricular administration of 
the studied substances, the rats were deeply anaes-
thetised with lethal doses of intraperitoneal injections 
of Nembutal (80 mg/kg of body weight). To obtain 
material suitable to perform Western blot analysis we 
used our previously published protocol [1]. Briefly, 
a total of 20 microdissected tissue samples (one from 
each animal) were obtained using a surgical micro-
scope from the right striatum, the one next to the 
administration site. All the samples were manually 
homogenised on ice with a Potter-Elvehjem tissue 
grinder in 4 volumes of ice cold homogenisation 
buffer (20 mM Tris-HCl pH 7.5; 0.25 M sucrose; 
10 mM EGTA; 2 mM EDTA) containing protease inhibi-
tors (1 mM AEBSF, 0.8 µM aprotynin; 50 µM bestatin; 
15 µM E-64, 20 µM leupeptin and 10 µM pepstatin A). 
Samples were centrifuged at 4°C, for 15 min, 14 000 rpm. 
The supernatant was collected and centrifuged at 
4°C, for 30 min, 14 000 rpm. To estimate the amount 
of protein in supernatant of the given sample the 
Lowry’s method was used. Denaturated 40-µg protein 
samples were electrophoretically separated on 12% 
Tris-SDS gels with Tris-glycine electrophoresis buffer 
and subsequently transferred onto a nitrocellulose 
membrane by semi-dry electroblotting. Quality of 
transfer was controlled by Ponceau S staining. The 
membranes were then blocked with 3% nonfat dry 
milk in tris-buffered saline (TBS) buffer (10 mM Tris pH 
7.6; 150 mM NaCl) for 2 h and incubated overnight 
at 4°C with primary antibody: monoclonal mouse 
anti-NeuN antibody, clone A60 (MAB377 Chemicon; 
1:500 dilution) diluted in 1.5% milk in TBST (TBS 
buffer supplemented with 0.05% Tween20). Having 
been washed 3 × 10 min with TBS, the blots were 
incubated for 2 h with secondary rabbit anti-mouse 
antibody, horseradish peroxidase conjugate (1:50000; 
Sigma, USA) diluted in TBST. The internal standard of 
b-actin was used under the abovementioned condi-
tions with mouse monoclonal anti-b-actin primary 
antibody (1:30 000; Sigma, USA) and rabbit anti-
mouse IgG, horseradish peroxidase-conjugated an-
tibody (1:50 000; Sigma, USA). A chemiluminescent 
signal was developed using the SuperSignal West Pico 
chemiluminescent system (Pierce, USA) and visualised 
on an X-ray film.
Quantitative analysis
In order to assess the level of synapsin I protein 
expression in the striatum, X-ray films were scanned 
and the optical density (OD) of bands was evaluated 
using Image J 1.38 software (National Institutes of 
Health, USA). Relative OD ratios were calculated by 
comparing the OD of synapsin I of each sample with 
the OD of its internal standard (b-actin). The differen-
ces in the relative OD of synapsin I between studied 
groups were evaluated.
Statistical analysis
Statistical analysis was performed using GraphPad 
InStat version 3.0a for Windows (GraphPad Software, 
San Diego, CA). In the first step Bartlett test and 
Kolmogorov-Smirnov test were performed to test the 
homogeneity of standard deviations (SD) and nor-
mal distribution of the data, respectively. Following 
significant one-way ANOVA, the post hoc Dunnett 
test was performed to assess differences between 
control and each of experimental groups. P < 0.05 
was considered statistically significant. The results 
of Western blot analyses (Fig. 1) were expressed as 
mean relative OD ± SD.
RESULTS
Antibody anti-NeuN, clone A60 (MAB377, Chemi-
con), recognises at least two major protein species 
migrating at approximately 45–50 kDa, by western of 
full brain extracts. In addition to the 45–50 kDa NeuN 
doublet, some neuronal cells lysate preparations show 
by western additional reactive bands at ~66 kDa, and 
between ~70–90 kDa [5, 13, 16]. In our study, in the 
supernatant obtained from rat’s striatum samples, 
the “classic” NeuN doublet species below 50 kDa 
was depleted, and only doublet of reactive bands at 
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approximately 76 an 78 kDa was observed (Fig. 1), 
which was in accordance with previously published 
reports [5, 13]. Study performed on P19 cells and 
adult mice nervous tissue by Kim et al. [13] showed 
that the peptide sequences from the upper band in-
cluded a sequence unique to synapsin Ia while peptide 
sequences from the lower band are all common to 
isoforms Ia and Ib. Therefore, the lower band could 
be synapsin Ib or a proteolytic fragment of synapsin 
Ia. Also, according to other studies performed on 
protein extracts of the early developing and adult 
mice brains [16], bands with this molecular weight 
present after western blot incubation with anti-NeuN 
antibody recognises synapsin I in postnatal period, 
while at prenatal period at this level it also recog-
nises another protein, most likely R3hdm2 [16]. On 
the basis of listed above data we are confident, that 
doublet of reactive bands observed at approximately 
76 and 78 kDa is synapsin I.
Two weeks after intraventricular administration of 
proteasome inhibitors, in each experimental group 
significant differences were found in the OD of sy-
napsin I protein within the striatum as compared with 
control group (Fig. 1). After MG-132 administration, 
the OD of synapsin I 76 kDa band was 61% lower 
(p < 0.01), while the OD of synapsin I 78 kDa band 
was 76% lower (p < 0.01). After lactacystin admini-
stration, the OD of synapsin I 76 kDa band was 42% 
lower (p < 0.01), while the OD of synapsin I 78 kDa 
band was 81% lower (p < 0.01). The smallest, but 
significant differences were observed after epoxomi-
cin administration, the OD of synapsin I 76 kDa band 
was 24% lower (p < 0.01), while the OD of synapsin 
I 78 kDa band was 29% lower (p < 0.01).
The analysis of synapsin I intensity on the brain 
sections stained with anti-NeuN antibody was not 
planned, because according to previous studies [13, 
16] this antibody does not recognise synapsin I on 
immunohistochemically stained sections.
DISCUSSION
Decreased level of synapsin I, similar to the one 
described above, has been reported formerly in natu-
rally occurred neuropathological conditions such as 
Alzheimer’s disease [10, 20], or during HIV-1 infection 
[7]. Significant depletion of synapsin I, was also ob-
served in experimental models of brain trauma such 
as transient middle cerebral artery occlusion [21] and 
mild brain fluid percussion injury [23]. Initially, the 
decrease of synapsin I observed during Alzheimer’s 
disease in the hippocampal formation [20], and ento-
rhinal cortex — even in cases characterised by the ear-
liest clinically detectable stage of the disease [10], was 
considered as an effect of a nonspecific loss of whole 
synapses. However, more recently, investigation of 
changes in the expression of several presynaptic and 
postsynaptic proteins in primary neurons treated with 
a low-molecular weight and high-molecular weight 
b-amyloid oligomers, revealed that both oligomers 
significantly reduced expression of several pre synaptic 
Figure 1. Densitometric analysis of synapsin I protein level in the rat’s striatum 2 weeks after intraventricular administration of proteasome 
inhibitors: MG-132, lactacystin or epoxomicin. The protein level is presented as a ratio of the optical density of studied protein to the internal 
standard of b-actin (relative optical density) (A). Significant decrease in the synapsin I protein level after proteasome inhibitors administration 
versus control is indicated by asterisk (**; p < 0.01). A representative blot, probe with antibody anti-neuronal nuclear antigen, with visible 
bands with molecular weight corresponding to synapsin I, is shown (B).
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proteins, including synapsin [11]. Since strong 
evidence exists for a central role of b-amyloid oligo-
mers in the pathogenesis of Alzheimer’s disease [3], 
changes in synapsin I levels observed in this disease 
seems to be specific response for pathological events 
triggered by presence of b-amyloid oligomers. As 
a specific change within viable nerve endings is treated 
also the decrease of synapsin Ib in nerve endings as-
sociated with HIV-1 infection. It has been proposed 
that depletion of synapsin I is linked to an abnormal 
regulation of the reserve pool of presynaptic vesicles 
of brain neocortex [7] and possibly causes long-term 
synaptic depression. Experimentally induced transient 
middle cerebral artery occlusion resulted in decreased 
mRNA levels of genes encoding synapsin Ia in the 
ischaemic cortex [21]. The authors of this study pos-
tulated that low level of level of this transcript could 
participate in disrupt neurotransmitter release and, 
thus, long-term potentiation after transient middle 
cerebral artery occlusion.
It has to be noted that the results of majority 
experimental studies [6, 11, 14, 23] link changes in 
the level of synapsin I protein with the activity of pro-
teasome. After the mild brain fluid percussion injury 
as an explanation of almost 60% reduce of synapsin I 
levels authors postulated proteasome activation via 
elevations in protein oxidation [23]. Used in the stu-
dies the proteasome inhibitor MG-132 attenuated 
synapsin I loss caused by b-amyloid oligomers [11], 
while lactacystin blocked synapsin decrease present 
during transcription-dependent long-term synaptic 
depression induced by administration of the neuro-
peptide Phe-Met-Arg-Phe-NH2 (FMRFa) [6]. Interest-
ing data has been published by Lazarevic et al. [14]. 
Treatment of cultures of control and silenced rat 
neurons with MG-132 for 6 h resulted in an increase in 
total cellular levels of cytomatrix-associated proteins 
Bassoon, ELKS/CAST, Munc13-1, RIM, and synapsin 
in control and silenced cultures. However, treatment 
with MG-132 for 24 or 48 h did not result in increase 
in protein levels as expected, but led to a downre-
gulation of multiple known UPS targets (e.g., RIM, 
Munc13-1, and liprin-a) and other presynaptic and 
postsynaptic scaffolding proteins such as Bassoon, 
ELKS/CAST, Homer, and synapsin. Authors concluded 
that the UPS regulates levels of cellular proteins in an 
extremely specific manner, and it is influenced by the 
activity status of neuronal networks, which may also 
explain results obtained in our study.
CONCLUSIONS
Described in the present manuscript substantial 
reduction of the striatal synapsin I — one of the 
most prominent neuron-specific phosphoproteins 
in the brain — observed 2 weeks after intraventri-
cular administration of proteasome inhibitors, is in 
accordance with previous in vivo and in vitro studies 
which indicate that neurons are very sensitive to the 
depletion of proteasome function [2, 4, 17, 28]. Be-
cause dopaminergic neurons are especially fragile to 
this depletion, and substantial loss of dopaminergic 
terminals in the striatum after proteasome inhibitors 
administration has been reported [15, 28], we assume 
that observed synapsin I level decrease may reflect 
changes in population of striatal neurons and/or 
nigrostriatal terminals. We realise that explanation 
of cellular mechanisms standing behind our findings 
needs more intensive studies, but we hope that pre-
sented data may be a valuable contribution to the 
discussion on the mechanisms linking UPS inhibition 
and survival of neurons.
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